Drug Trial Radar · NCT05559099
Tecovirimat for Treatment of Monkeypox Virus
Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
597
Actual
Start
Oct 10, 2022
Primary completion
Sep 3, 2024
Study completion Sep 3, 2024
Sponsor
- Sponsor type
- NIH
- Collaborators
- Institut National de Recherche Biomedicale (INRB)
- First posted
- Sep 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC). Participants will be randomly assigned to receive oral tecovirimat plus SOC or placebo plus SOC for 14 days.
Conditions
- Monkeypox
Interventions
Tecovirimat Oral CapsuleDrug
200 mg capsules Number of capsules and frequency of dosage will be based on participant weight: * ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg) * 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg) * 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg) * 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg) * 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg) * 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)
PlaceboDrug
Capsules to match tecovirimat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Lesion ResolutionTime frame: Up to day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
L'Hôpital Général de Référence de Kole
Kole, Democratic Republic of the Congo
L'Hôpital Général de Référence de Tunda
Tunda, Democratic Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.